See also this year's filing and all EDGAR filings for this company.
PDF Report 0001479290_2021_Revance_Therapeutics_Inc.pdf
Logs
| info | Minor missing amount for aggregate added to remainder | industry.us_generic | {'aggregate': 'Expenses', 'missing_ratio': 0.01609810765377423, 'aggregate_val': 301015000, 'exp_sum': 296246000, 'exp_to_value': {'CostOfGoodsAndServicesSold': 0, 'SellingGeneralAndAdministrativeExpense': 151846000, 'ResearchAndDevelopmentExpense': 125795000, 'remainder_Expenses': 18605000}} |
Graph
Absolute values for 0001479290, Revance Therapeutics Inc.
| xvar | xval | |
|---|---|---|
| 0 | AssetsCurrent | 450,003,000 |
| 1 | IntangibleAssetsNetIncludingGoodwill | 218,307,000 |
| 2 | PropertyPlantAndEquipmentNet | 17,499,000 |
| 3 | remainder_Assets | 34,411,000 |
| 4 | LiabilitiesCurrent | 60,964,000 |
| 5 | LiabilitiesNoncurrent | 104,440,000 |
| 6 | remainder_Liabilities | 180,526,000 |
| 7 | CostOfGoodsAndServicesSold | 0 |
| 8 | SellingGeneralAndAdministrativeExpense | 151,846,000 |
| 9 | ResearchAndDevelopmentExpense | 125,795,000 |
| 10 | remainder_Expenses | 23,374,000 |
| 11 | remainder_Revenues | 15,325,000 |
| 12 | remainder_NetIncome | 3,601,000 |
| 13 | remainder_ComprehensiveNetIncome | -3,000 |
| yvar | yval | |
|---|---|---|
| 0 | Assets | 720,220,000 |
| 1 | Liabilities | 345,930,000 |
| 2 | Expenses | 301,015,000 |
| 3 | Revenues | 15,325,000 |
| 4 | StockholdersEquity | 374,290,000 |
| 5 | NetIncome | -282,089,000 |
| 6 | ComprehensiveNetIncome | -282,090,500 |
| 7 | BaseVar | 693,047,000 |
| 8 | EconomicCapitalRatio | 0.678 |
Edgar->Model Mapping
Feature Distribution
Change over Time
